Safety and Preliminary Efficacy Assessment of AZD7789 in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Trial Identifier: D9571C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: March 2022
Primary Completion Date: August 2024
Study Completion Date: September 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Italian Translation
French (France) Translation
French (Canada) Translation
Spanish (US) Translation
Spanish (Spain) Translation
English (Great Britain) Translation
English (Canada) Translation
Danish Translation

Trial Locations

Country Location
CA, Ontario Toronto, Ontario, CA, M5G 1X6
CA, QC Montreal, QC, CA, H3T 1E2
DK København Ø, DK, 2100
ES Valencia, ES, 46010
FR Lille, FR, 59037
GB Manchester, GB, M20 4BX
GB Oxford, GB, 0X3 7LJ
IT Bologna, IT, 40138
IT Napoli, IT, 80131
US, CA Duarte, CA, US, 91010
US, FL Miami, FL, US, 33136
US, MN Rochester, MN, US, 55905
US, NY New York, NY, US, 10065
US, TX Houston, TX, US, 77030